肥胖与类风湿关节炎患者新发慢性阿片类药物使用的风险
基于FORWARD数据库19794例类风湿关节炎患者的前瞻性队列分析显示,肥胖与慢性阿片类药物使用风险升高相关,严重肥胖(BMI>35 kg/m2)者总体使用风险调整后HR为1.74,强阿片类为2.11;约15%的总体使用和24%的强阿片类使用可归因于肥胖。
要点
- 严重肥胖(BMI>35)增加RA患者慢性阿片类使用风险,调整后HR 1.74。
- 严重肥胖者强阿片类使用风险更高,调整后HR 2.11。
- 肥胖归因风险占总体阿片使用的15%,强阿片类的24%。
核心结论
- 肥胖与类风湿关节炎患者新发慢性阿片类药物使用风险显著升高相关,严重肥胖者风险更高。
- 约四分之一的强阿片类新发使用可归因于肥胖,提示公共卫生影响重大。
研究设计与样本
- 基于FORWARD数据库的类风湿关节炎参与者队列,每半年调查弱和强阿片类药物使用情况。
- 新发慢性阿片使用定义为连续两次调查(约7-12个月)报告使用,采用Cox比例风险模型分析。
- 共纳入19794名参与者,随访93254人年,调整人口学、吸烟、病程、RA治疗、家庭收入和教育水平。
主要发现
- 随访期间2802例出现新发慢性阿片使用。
- 相比正常BMI,严重肥胖(BMI>35 kg/m2)与总体慢性阿片使用风险升高相关(调整后HR 1.74,95%CI 1.72-2.04,P<0.0001)。
- 严重肥胖与强阿片类使用风险升高相关(调整后HR 2.11,95%CI 1.64-2.71,P<0.001)。
- 关联部分由肥胖组更高的合并症、疼痛和残疾解释。
- 肥胖归因风险占总体阿片使用的15%,强阿片类使用的24%。
关键数值与推荐
- 新发慢性阿片使用定义:连续两次半年度调查(约7-12个月)报告使用。
- 严重肥胖定义:BMI>35 kg/m2。
- 调整后HR:总体阿片使用1.74(95%CI 1.72-2.04,P<0.0001),强阿片类2.11(95%CI 1.64-2.71,P<0.001)。
- 肥胖归因风险:总体阿片使用15%,强阿片类使用24%。
临床怎么用
- 对RA患者应评估肥胖,作为慢性阿片类使用风险的潜在可干预因素。
- 预防或减轻肥胖的干预可能有助于减少阿片类药物的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The present study was undertaken to evaluate whether the rate of incident chronic opioid use is higher in obese patients with rheumatoid arthritis (RA). METHODS: Participants with RA in the FORWARD databank were asked about their use of weak and strong opioid medications on semiannual surveys. Incident chronic opioid use was defined as new reported use extending over 2 contiguous surveys (~7-12 months). Cox proportional hazards models were used to evaluate associations between body mass index (BMI) at enrollment and incident chronic opioid use (overall use and strong opioid use). Models adjusted for demographics, smoking, disease duration, RA treatments, household income, and education level. The predicted 5-year cumulative incidence was calculated from Cox models. RESULTS: Among 19,794 participants, 2,802 experienced an incident episode of chronic opioid use over 93,254 person-years of follow-up. Higher BMI was associated with higher risk of chronic opioid use. Severe obesity (BMI >35 kg/m2 ) was associated with a higher risk of overall use (adjusted hazard ratio [HRadj ] 1.74 [95% confidence interval (95% CI) 1.72-2.04], P < 0.0001) and strong opioid use (HRadj 2.11 [95% CI 1.64-2.71], P < 0.001) compared to normal BMI. This association was partially explained by greater comorbidity, pain, and disability in obese groups. The attributable risk for obesity was 15% of overall opioid use and 24% of strong opioid use. CONCLUSION: Obesity is associated with a substantially higher risk of incident chronic opioid use. Approximately 1 in 4 cases of incident use of strong opioids may be attributable to obesity, suggesting a major public health impact. Interventions to prevent or reduce obesity could have an important impact on the use of opioids.
引用
- Baker JF, Stokes A, Pedro S, et al. Obesity and the Risk of Incident Chronic Opioid Use in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021. PMID: 32475039. doi:10.1002/acr.24341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。